Sydney Antibody Therapeutics

Conference

7th & 8th May 2025
Main-Image001

Speakers

Meet our Speakers

President of the Antibody Society (2022-2023), Professor of Molecular Immunology and Director of Translational Immunology, University of Southampton

2018 Nobel Prize Winner
Trinity College, Cambridge University

Professor of Biochemistry, University of Auckland

local & international speakers

Adam Clarke

AbCellera Biologics

Alvin Chew

GenScript

Ben Kiefel

Myrio Tx

Brad Walsh

GlyTherix

Christoph Hagemeyer

Monash University

Colby Souders

Twist Bioscience

Chris Smith

Brandon Capital

Clarissa Whitehead

Burnett Institute

Daniel Christ

Garvan Institute

Hayley Ramshaw

Monash University

Jason Gill

Teva Pharmaceuticals

Kailash Kumar Vinu

Actimo Labs

Karlheinz Peter

Melbourne University

Lisa Williams

Alkira Bio

Maggie Ma

Promega

Martha Perez

Unchained Labs

Peter Janes

La Trobe University

Ross Dickins

Monash University

Sacha Zinn

Garvan Institute

Steve Gledhill

FB Rice

Program

Day 1

7th May 2025

KEYNOTE

Greg Winter

Cambridge University
A tale of two antibodies

Adam Clarke

AbCellera Biologics
AbCellera's TCE platform

SESSION ONE – ANTIBODIES IN CARDIOLOGY

Karlheinz Peter

Melbourne University
Single chain antibodies for theranostic approaches in cardiovascular diseases

Christoph Hagemeyer

Monash University
Conformation-Specific Antibodies for the Therapy of Vascular Disease

SESSION TWO – ANTIBODIES IN ONCOLOGY

Jason Gill

Teva Pharmaceuticals
Novel approaches to cancer immunotherapy: Next generation Immunocytokines

Peter Janes

La Trobe University
Novel antibody drug conjugates targeting tumours and their microenvironment

Ben Kiefel

Myrio Tx
Retained Display (ReD)TM: Myrio Therapeutics’ leading technology for discovery of peptide-HLA binders.

Ross Dickins

Monash University
Immunosuppressive biologics targeting the CD80:PD-L1 duplex

Brad Walsh

GlyTherix
Development of a novel tumour targeting chimeric antibody - Miltuximab

SESSION THREE – NEW TARGETS

Alvin Chew

GenScript
Next-Gen Biologics Production: Case Studies from mAbs to Overcoming BsAb Challenges

Lisa Williams

Alkira Bio
A LASEREDD focus on GPCR-targeting antibodies

Remy Robert

Monash University
Antibody mediated depletion of pathogenic cells through their chemokine receptor signatures

Day 2

8th May 2025

KEYNOTE

Juliet Gerrard

University of Aukland
Science and science advice in New Zealand: a changing landscape

Daniel Christ

Garvan Institute
Targeting challenging antigens with monoclonal antibodies

SESSION FOUR – ANTIBODY IP AND CAPITAL LANDSCAPE

Steve Gledhill

FB Rice
Antibody patents – challenges and strategies

Chris Smith

Brandon Capital
The Antibody Therapeutics Landscape: An Australian VC Perspective

SESSION FIVE – PITCH PRESENTATIONS

Sacha Zinn

Garvan Institute
Enhancing immunisations using mRNA encoded antibodies

Kailash Kumar Vinu

Actimo Labs
ActiMap – Advancing Epitope Mapping Through AI-Driven In-Silico Modeling

Maggie Ma

Promega
Advancing Immunotherapy Development with Comprehensive Fc Effector Function Assays

Hayley Ramshaw

Monash Univiersity
Monash Antibody Discovery Platform Beacon Antibody Discovery instrument

SESSION SIX – ANTIBODY ENGINEERING FOR FUNCTION

KEYNOTE

Sally Ward

University of Southhampton
Targeting FcRn for the therapy of autoimmunity

Clarissa Whitehead

Burnett Institute
Stellabody® transforms the potency of antibody and Ig-like biologics.

Colby Souders

Twist Bioscience
Leveraging De Novo Sequence Design and DNA Writing for Target-Specific in vitro Library Discovery

Secure your spot for Sydney Antibody Therapeutics 2025

Venue

CONFERENCE

Join us at the N’Galawa Terrace in the Taronga Centre at Taronga Zoo

ACCOMMODATION

Stay in the city

Head over to the Zoo by ferry or a 20 minute taxi ride.

View ferry timetable

Stay at the zoo

Enjoy an overnight stay at Taronga Zoo Sydney for a truly unique and immersive experience amongst the wild.

Book with Taronga Zoo

Silver level sponsorships are still available

Take this unique opportunity to gain brand awareness and visibility within the Australian and International Antibody Therapeutic community